Mircea Ivan (ORCID 0000-0003-3424-6642) is a highly influential molecular biologist whose early work in William Kaelin's laboratory at Brigham and Women's Hospital/Dana-Farber helped define the oxygen-sensing machinery that underpinned the 2019 Nobel Prize in Physiology or Medicine. OpenAlex attributes 184 works and ~17,032 citations (h-index 47) to the matched author profile; the Semantic Scholar-style profile reports h-index 42 with 14,969 citations over 119 papers β the discrepancy partly reflects author-disambiguation noise and inclusion of conference abstracts. Two other profiles share the name (h-index 15 and 1), and at least one paper in the dataset β a Voronovskaya-type theorem in approximation theory β is almost certainly a different Mircea Ivan and should be excluded.
His first-author 2001 Science paper demonstrated that HIFΞ± is targeted for VHL-mediated destruction by proline hydroxylation, directly establishing the oxygen-dependence of this post-translational mark . Follow-up first-author work biochemically purified a mammalian HIF prolyl hydroxylase and showed pharmacological inhibition, prefiguring the PHD-inhibitor drug class (roxadustat, daprodustat) . He also co-authored the crystal-structure study of hydroxyproline recognition by pVHL and the VHL-binding/ubiquitination mechanism paper .
Later, at Tufts and Indiana University, Ivan pivoted to hypoxic regulation of the non-coding transcriptome. He is senior author of the influential "A MicroRNA Signature of Hypoxia" , the miR-210/ISCU mitochondrial metabolism study , and work connecting hypoxia-driven miRNA downregulation of DNA repair , plus hypoxia-DICER epigenetics, lincNORS sterol homeostasis, NLUCAT1, and the EPHOSS/oxygen-shock stem-cell transplantation discovery in Cell .
Many highly-cited papers (structure papers, miR-221/222 resistance work) credit Ivan in middle authorship, so first/senior contributions must be parsed carefully; abstract/conference records inflate the 119-184 paper count. Author-name collision with a mathematician contaminates disambiguation. Metabolic/hypoxia work relies heavily on cell-line and murine models (e.g., OIR retinopathy, xenografts), limiting clinical generalizability, and several papers exist only as AACR abstracts without peer-reviewed full data. Citations remain strong (500-950/yr through 2026), indicating durable influence. Confidence: high on metrics, moderate on attribution of specific claims to Ivan's own leadership.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.